Qilian International Holding Group

Qilian International Holding Group Ltd. is a pharmaceutical and chemical company. It focuses on the research, development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Licorice products include Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan Licorice Liquid Extract. The Oxytetracycline products consists of Qilian Shan Oxytetracycline Tablets and Qilian Shan Oxytetracycline Active Pharmaceutical Ingredients (API). The TCMD product includes Ahan antibacterial paste, which is made from a mixture of traditional Chinese herbal ingredients. The heparin product includes Heparin Sodium Preparations. The Sausage Casings products include Zhu Xiaochang Sausage Casings, which are all-natural food products used for culinary purposes. The Fertilizer products is composed of Xiongguan Organic Fertilizer and Xiongguan Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Jiuquan, China.

Earnings data Q1 2024

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:  QLI ) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement. The Company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period.

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

JIUQUAN, China , July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), dated July 13, 2023, that the Company is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on The Nasdaq Global Market (the "Nasdaq Global Market"). The Notification Letter is only a notification of deficiency and not a notice of delisting.

Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

JIUQUAN, China , April 26, 2023 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, previously announced that on February 16, 2023, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule 5250(c)(1) for continued listing (the "Rule") as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022.  On April 19, 2023, the Company filed the Form 20-F, and on April 20, 2023, the Company received a second letter from NASDAQ stating that based on the April 19, 2023 filing of the Company's Form 20-F, NASDAQ has determined that the Company complies with the Rule.

Qilian Received a Letter from Nasdaq Related to Regain Compliance

JIUQUAN, China , Feb. 23, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced it has received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on February 16, 2023 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022, Qilian is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of Qilian's ordinary shares on Nasdaq.

Qilian Received Notification of Deficiency from Nasdaq Related to not timely Filing of Annual Report Form 20-F

JIUQUAN, China , Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow.

Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

JIUQUAN, China , Sept. 30, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022

JIUQUAN, China, Feb. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ended September 30, 2021. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, "The fiscal year 2021 was an excellent year for the Company.

Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results

JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administration's approval for selling nitrofurantoin enteric-coated tablets.

Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets

JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Company's board of directors. Dear Shareholders, As a well-established manufacturer with a long history in the Chinese pharmaceuticals and chemical industry, the Company was officially listed on Nasdaq Global Market ("Nasdaq") in January 2021.

Qilian International Holding Group Limited Releases 2022 Chairman Letter

JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), have been included in the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province (the "List").

Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province

JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that the Company recently started, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), developing a new drug, Vitacoenzyme (the "Drug"), that aims to  prevent gastric cancer.

Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention

JIUQUAN, China, Nov. 1, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Company donated Gan Di Xin®, its self-developed antitussive and expectorant medicine, and 75% alcohol disinfectant, with an aggregate value of more than RMB500,000 to the government of Suzhou District, Jiuquan City to help control the spread of local COVID-19 epidemic newly reported in October.

Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic

JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer production facility. As a result, the Company's annual production capacity of organic fertilizers has increased to 30,000 tons.

Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production

JIUQUAN, China, Oct. 13, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "Gansu QLS"), it has received Certificate of a Pharmaceutical Product (the "Export Certificate") from Gansu Province Drug Administration, which approves the export of its Qilian Shan® Oxytetracycline APIs (Active Pharmaceutical Ingredients) (the "API") to Egypt.

Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt

Jiuquan, China, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021.

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021

Jiuquan, China, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company, through its PRC subsidiary Chengdu Qilianshan Biotechnology Co., Ltd. (“Chengdu QLS”), entered into an agreement (the “Agreement”) with Chongqing Tongnan District Government (“CTDG”). Pursuant to the Agreement, the Company's new pig by-product processing facility (the “Project”) will be located in Tongnan High-tech Zone. CTDG agrees to provide the Company with preferential policies and support funds.

Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone

Jiuquan, China, July 09, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company, through its PRC subsidiary Chengdu Qilianshan Biotechnology Co., Ltd., has entered into an investment agreement (the "Agreement") with Chongqing Jin Tong Industrial Construction Investment Co. Ltd. (“CJT”) on July 5, 2021, for the construction of a pig by-product processing facility (the “Project”) in Chongqing.

Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in Chongqing

Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections. In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.

Qilian International Holding Group Limited Announces Inclusion of 16 Products into China's National Reimbursement Drugs List

The stock price of Qilian International Holding Group Ltd (NASDAQ: QLI) increased by over 10% pre-market. This is why it happened.

QLI Stock Price Increased Over 10% Pre-Market: Why It Happened

Jiuquan, China, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its financial results for the fiscal year ended September 30, 2020.

Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results

Jiuquan, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company will complete the first phase expansion of its new organic fertilizer production facility and put it into production in Jiuquan City, Gansu Province by March 2021. The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.

Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021

New York, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of the initial public offering (“IPO”) for its client Qilian International Holding Group Limited (the “Company”), marking the first IPO in 2021 to which Univest acts as the sole book-running manager. A total of 5,750,000 ordinary shares of the Company, including 750,000 ordinary shares pursuant to Univest's full exervise of the over-allotment option, are offered at a public offering price of $5.00 per share, raising aggregate gross proceeds of $28,750,000, before deducting underwriting discounts and other related expenses. The ordinary shares began trading on the Nasdaq Global Market on January 12, 2021 under the ticker symbol “QLI”.

Univest Securities, LLC. Announces Closing of IPO for its Client Qilian International Holding Group Limited (Nasdaq: QLI)

Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

Qilian International Holding Group Limited Announces Closing of Initial Public Offering

Qilian (QLI) is catching the eyes of investors on Tuesday as shares of its stock started trading today via the company's IPO. The post Qilian IPO: 10 Things for Potential QLI Stock Investors to Know About the Chinese Pharma appeared first on InvestorPlace.

Qilian IPO: 10 Things for Potential QLI Stock Investors to Know About the Chinese Pharma

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

News for Qilian International Holding Group Stock (QLI)